Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms.

ISRN Dermatology Pub Date : 2011-01-01 Epub Date: 2011-04-10 DOI:10.5402/2011/848909

Rancés Blanco, Enrique Rengifo, Charles E Rengifo, Mercedes Cedeño, Milagros Frómeta, Adriana Carr

{"title":"Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms.","authors":"Rancés Blanco, Enrique Rengifo, Charles E Rengifo, Mercedes Cedeño, Milagros Frómeta, Adriana Carr","doi":"10.5402/2011/848909","DOIUrl":null,"url":null,"abstract":"<p><p>The evaluation of 14F7 Mab (anti-N-glycolyl GM3 ganglioside) immunorecognition in normal skin, cutaneous malignant melanoma (CMM), and in lymph node metastases (LNM) has been previously reported. In this work we extended the study to benign (BMN) and dysplastic (DMN) melanocytic nevi, basal (BCC), and squamous cell carcinoma (SCC). Immunohistochemical assays with 14F7 followed by a biotinylated link universal and streptavidin-AP in normal and pathological tissues were made. No reaction of 14F7 in normal skin (0/10) as well as a low reactivity in BMN (2/11) and DMN (1/7) was detected. A limited staining in BCC (2/13) and in SCC (4/8) was also evidenced, while 14F7 Mab were mostly reactive in CMM (28/28) and in LNM (6/7). These results suggest that 14F7 reactivity could be closely related with the more aggressive biological behavior of CMM and also support the use of NeuGcGM3 as target for both passive and active melanoma immunotherapy.</p>","PeriodicalId":14682,"journal":{"name":"ISRN Dermatology","volume":"2011 ","pages":"848909"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2011/848909","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5402/2011/848909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/4/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 35

Abstract

The evaluation of 14F7 Mab (anti-N-glycolyl GM3 ganglioside) immunorecognition in normal skin, cutaneous malignant melanoma (CMM), and in lymph node metastases (LNM) has been previously reported. In this work we extended the study to benign (BMN) and dysplastic (DMN) melanocytic nevi, basal (BCC), and squamous cell carcinoma (SCC). Immunohistochemical assays with 14F7 followed by a biotinylated link universal and streptavidin-AP in normal and pathological tissues were made. No reaction of 14F7 in normal skin (0/10) as well as a low reactivity in BMN (2/11) and DMN (1/7) was detected. A limited staining in BCC (2/13) and in SCC (4/8) was also evidenced, while 14F7 Mab were mostly reactive in CMM (28/28) and in LNM (6/7). These results suggest that 14F7 reactivity could be closely related with the more aggressive biological behavior of CMM and also support the use of NeuGcGM3 as target for both passive and active melanoma immunotherapy.

Abstract Image

查看原文本刊更多论文

抗n -糖基GM3神经节苷脂14F7单克隆抗体在一些良恶性皮肤肿瘤中的免疫组织化学反应性

14F7 Mab(抗n -羟基甘油酯GM3神经节苷脂)在正常皮肤、皮肤恶性黑色素瘤(CMM)和淋巴结转移(LNM)中的免疫识别评估此前已有报道。在这项工作中，我们将研究扩展到良性(BMN)和发育不良(DMN)黑素细胞痣、基底(BCC)和鳞状细胞癌(SCC)。在正常组织和病理组织中分别用14F7进行免疫组化分析，然后用生物素化的通用链接和链霉亲和素ap。14F7在正常皮肤无反应(0/10)，在BMN(2/11)和DMN(1/7)中检测到低反应性。在BCC(2/13)和SCC(4/8)中也有有限的染色，而14F7 Mab在CMM(28/28)和LNM(6/7)中主要有反应。这些结果表明，14F7的反应性可能与CMM更具侵袭性的生物学行为密切相关，也支持NeuGcGM3作为被动和主动黑色素瘤免疫治疗的靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ISRN Dermatology

自引率

0.00%

发文量